Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
As of the edition of 20 October 2026, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical runs 24 drugs; it is on route A at 3 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Active | 18 |
| Stopped | 4 |
| Status not established | 2 |
| Total | 24 |
Where it needs a new molecule
Route A at 3 targets, route B at 0 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 16 trials led
- Skin and connective tissue: 11 trials led
- Immune system: 7 trials led